Australia markets closed

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.1300+0.0700 (+3.40%)
As of 03:25PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 78.95M
Enterprise value -66.88M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.61
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.53

Trading information

Stock price history

Beta (5Y monthly) 2.78
52-week change 3-25.63%
S&P500 52-week change 321.23%
52-week high 34.2980
52-week low 31.3300
50-day moving average 33.0113
200-day moving average 32.4849

Share statistics

Avg vol (3-month) 3367.61k
Avg vol (10-day) 3190.69k
Shares outstanding 538.33M
Implied shares outstanding 638.33M
Float 826.94M
% held by insiders 12.19%
% held by institutions 162.96%
Shares short (28 Mar 2024) 41.01M
Short ratio (28 Mar 2024) 41.81
Short % of float (28 Mar 2024) 43.59%
Short % of shares outstanding (28 Mar 2024) 42.63%
Shares short (prior month 29 Feb 2024) 4783.58k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-37.97%
Return on equity (ttm)-64.42%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -126.12M
Net income avi to common (ttm)-117.67M
Diluted EPS (ttm)-3.0900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)147.42M
Total cash per share (mrq)3.85
Total debt (mrq)1.58M
Total debt/equity (mrq)1.22%
Current ratio (mrq)5.36
Book value per share (mrq)3.41

Cash flow statement

Operating cash flow (ttm)-100.75M
Levered free cash flow (ttm)-60.9M